Dianthus Therapeutics (NASDAQ:DNTH) announced a licensing deal worth up to $1B with Nanjing Leads Biolabs on Thursday to obtain exclusive rights to an autoimmune disease therapy developed by the ...
NEW YORK and WALTHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to ...
DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results